ProPhase Labs Teams up with Certis Oncology to Accelerate Development of Novel Linebacker Compound
“We have tested the novel Linebacker compound against hundreds of cancers and thousands of pathways, but will continue testing to the extent we believe useful data may be obtainable,” says Ted Karkus, CEO of ProPhase Labs.
- “We have tested the novel Linebacker compound against hundreds of cancers and thousands of pathways, but will continue testing to the extent we believe useful data may be obtainable,” says Ted Karkus, CEO of ProPhase Labs.
- “Our team is very pleased to be working with ProPhase on the Linebacker initiative.
- “Savvy investors expect this now, and with good reason, and ProPhase will continue to lead the pack and push the boundaries forward.
- We are looking forward to initiating Phase I human studies next year at a modest budget of approximately $3+ million dollars for all planned studies.